Amorchem
7
19M
5
0.54
2
0.29
1
- Areas of investment
Summary
Amorchem appeared to be the VC, which was created in 2011. The fund was located in North America if to be more exact in Canada. The leading representative office of defined VC is situated in the Montru00e9al.
Deals in the range of 1 - 5 millions dollars are the general things for fund. The fund is generally included in less than 2 deals every year. The important activity for fund was in 2018. Considering the real fund results, this VC is 47 percentage points more often commits exit comparing to other organizations.
Among the most popular portfolio startups of the fund, we may highlight Semathera, Inversago Pharma. Moreover, a startup needs to be at the age of 2-3 years to get the investment from the fund. For fund there is a match between the country of its foundation and the country of its the most frequent investments - Canada. The fund has exact preference in some founders of portfolio startups. Among the most successful fund investment fields, there are Pharmaceutical, Biotechnology.
The usual cause for the fund is to invest in rounds with 4 partakers. The meaningful sponsors for the fund in investment in the same round are Accel-Rx Health Sciences Accelerator, Tarnagulla Ventures, Senju Pharmaceutical.
This organization was formed by Elizabeth Douville, Inu00e8s Holzbaur.
Investments analytics
Analytics
- Total investments
- 7
- Lead investments
- 2
- Exits
- 1
- Rounds per year
- 0.54
- Follow on index
- 0.29
- Investments by industry
- Biotechnology (7)
- Health Care (5)
- Pharmaceutical (4)
- Biopharma (4)
- Medical (4) Show 4 more
- Investments by region
-
- Canada (7)
- Peak activity year
- 2020
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 12
- Group Appearance index
- 1.00
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| Inversago Pharma | 17 Oct 2022 | Biotechnology, Health Care, Medical, Pharmaceutical, Biopharma | Late Stage Venture | 75M | Quebec, Montreal, Canada |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.